Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Compare the risk profiles of SP 500 versus bonds for retirees, highlighting diversification benefits and income stability.
21,457 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
A new analysis shows Microsoft’s AI-driven revenue pace hitting fresh highs, suggesting meaningful upside for patient...
Greg Abel delivers his first annual letter as Berkshire’s CEO, outlining continuity after a $4.5 billion write-down o...
When a high-flying IPO lands, the real work begins. Here are five practical milestones that space tech investors shou...
Ready to take control of your rental portfolio in 2026? This guide shows you how to get your rental business organize...
Want to protect cash flow while staying on the right side of the law? This guide shows real estate investors legally ...
A biotech insider trade draws attention after an FDA setback. This article unpacks the CFO's $720k stock sale at Disc...
Meta Platforms is advancing Arena, a stand-alone prediction markets app that would start with non-cash points and cou...
Ethereum stands on the edge of a rare capitulation pattern, with seven straight monthly declines likely. Traders eye ...
Binance withdraws its Greece bid and says it has one week to secure an EU license. The company reiterates that binanc...
RadNet’s 2025 earnings outlook hinges on imaging volumes, payer dynamics, and cost discipline. This guide breaks down...
Enrollment of international students fell sharply as policy shifts took hold, triggering sharp revenue declines for c...